近年来，组织工程的快速发展增加了作为新型策略制造功能性三维（3D）组织和器官模型用于制药研究的三维生物打印技术的重要性。3D生物打印技术为消除传统细胞培养方法在药物筛选过程中的许多问题带来了希望。然而，由于生物墨水、先进打印机和对人类组织结构的深入理解的发展所涉及的困难众多，这项技术在临床应用上仍有很长的道路要走。本综述介绍和讨论了与相对较为知名的挤压式生物打印（EBB）、喷射式生物打印（JBB）和光聚合物化生物打印（VPB）相关的工作，以及该领域的最新进展和限制。接下来，我们讨论了在体外模型的最新研究，包括肝脏、肾脏、肺、心脏、肠道、眼睛、皮肤以及神经和骨组织，它们在新药开发中具有潜在应用。版权所有 © 2023 Elsevier B.V. 保留所有权利。

Rapid development of tissue engineering in recent years has increased the importance of three-dimensional (3D) bioprinting technology as novel strategy for fabrication functional 3D tissue and organoid models for pharmaceutical research. 3D bioprinting technology gives hope for eliminating many problems associated with traditional cell culture methods during drug screening. However, there is a still long way to wider clinical application of this technology due to the numerous difficulties associated with development of bioinks, advanced printers and in-depth understanding of human tissue architecture. In this review, the work associated with relatively well-known extrusion-based bioprinting (EBB), jetting-based bioprinting (JBB), and vat photopolymerization bioprinting (VPB) is presented and discussed with the latest advances and limitations in this field. Next we discuss state-of-the-art research of 3D bioprinted in vitro models including liver, kidney, lung, heart, intestines, eye, skin as well as neural and bone tissue that have potential applications in the development of new drugs.Copyright © 2023 Elsevier B.V. All rights reserved.